Danish company Bactolife has raised over €30 million in Series B funding to commercialize Binding Proteins, a new food, feed, and dietary supplement ingredient produced through precision fermentation. The funding, led by Cross Border Impact Ventures (CBIV) and EIFO, will support the execution of a human study program across the US, EU, Asia, and LMICs, as well as the scaling of manufacturing and supply operations to meet global demand.

Bactolife plans to launch its first Binding Protein products in the US this year under the brand Helm, with future expansion into Asia and Europe. The company aims to make the technology accessible to women and children in LMICs, believing that its Binding Proteins are a significant advancement in gut health solutions. CEO Sebastian Søderberg expressed excitement about the funding, stating that it will enable the company to clinically validate, scale, and commercialize their innovative products, ultimately transforming gut health with novel Binding Proteins.